Key result
HRV-biofeedback shows strong evidence of clinical benefit in CAD, hypertension, and pain.
Why the study?
Does heart-rate variability biofeedback improve clinical outcomes in patients with chronic conditions such as CHD, hypertension, diabetes, and cancer?
Does heart-rate variability biofeedback improve clinical outcomes in patients with chronic conditions such as CHD, hypertension, diabetes, and cancer?
Answers are grounded in this paper and cite their sources.
Heart-rate variability biofeedback has a high level of evidence for providing clinical benefits in coronary heart disease, hypertension, and pain, though evidence remains poor for diabetes and dementia.
The vagus or "wandering" nerve is the main branch of the parasympathetic nervous system (PNS), innervating most internal organs crucial for health. Activity of the vagus nerve can be non-invasively indexed by heart-rate variability parameters (HRV). Specific HRV parameters predict less all-cause mortality, lower risk of and better prognosis after myocardial infarctions, and better survival in cancer. A non-invasive manner for self-activating the vagus is achieved by performing a slow-paced breathing technique while receiving visual feedback of one's HRV, called HRV-biofeedback (HRV-B). This article narratively reviews the biological mechanisms underlying the role of vagal activity and vagally mediated HRV in hypertension, diabetes, coronary heart disease (CHD), cancer, pain, and dementia. After searching the literature for HRV-B intervention studies in each condition, we report the effects of HRV-B on clinical outcomes in these health conditions, while evaluating the methodological quality of these studies. Generally, the levels of evidence for the benefits of HRV-B is high in CHD, pain, and hypertension, moderate in cancer, and poor in diabetes and dementia. Limitations and future research directions are discussed.
No takes yet. Share an insight, caveat, or question.
Gitler et al. (2022) conducted a review in Coronary heart disease, hypertension, pain, cancer, diabetes, and dementia. Heart rate variability biofeedback (HRV-B) was evaluated. HRV-biofeedback demonstrates high levels of evidence for clinical benefits in coronary heart disease, pain, and hypertension, moderate evidence in cancer, and poor evidence in diabetes and dementia.
Synapse has enriched 10 related papers. Consider them for comparative context: